AI Medical Technology today announced the successful closure of an oversubscribed bridge financing round worth SEK12 (US$1m). Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders.
The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis of malignant melanomas.
Results from a prospective, multicentre, peer-reviewed clinical trial recently published in the British Journal of Dermatology showed that Dermalyser had a remarkably high diagnostic precision1, outperforming both primary care physicians and specialist dermatologists.
Christoffer Ekström, CEO of AI Medical Technology comments: “I am delighted to be raising more money to support the ongoing development of Dermalyser. To have yet another oversubscribed round just shows that Dermalyser is in a league of its own when it comes to new diagnostic tools for skin cancer. With fantastic clinical results, excellent user feedback, and a passionate team who really believe in making a difference, we will continue to move from strength to strength. Our roadmap is now consolidated – we will raise more funds in a Series A round this year and plan for an IPO in 2027-2028.”
Henrik Jerner, CEO of Northern Venture CapSek, added: “We are extremely impressed with the results achieved in the multicenter, clinical trial thereby further increasing our confidence that AI Medical Technology and Dermalyser will be successful, and we are happy to participate in the investment round alongside other current and new shareholders.”
